{
  "study_id": "LA-2024-001",
  "title": "Phase II Clinical Trial - Novel KRAS G12C Inhibitor in NSCLC",
  "sponsor": "LifeArc Research",
  "status": "Active",
  "start_date": "2024-03-15",
  "phase": "Phase II",
  "indication": "Non-Small Cell Lung Cancer",
  "target": "KRAS G12C mutation",
  "primary_endpoints": [
    "Objective Response Rate (ORR)",
    "Duration of Response (DoR)"
  ],
  "secondary_endpoints": [
    "Progression-Free Survival (PFS)",
    "Overall Survival (OS)",
    "Safety and Tolerability"
  ],
  "enrollment": {
    "target": 120,
    "current": 87,
    "sites": 12
  },
  "inclusion_criteria": [
    "Age >= 18 years",
    "Histologically confirmed NSCLC",
    "Documented KRAS G12C mutation",
    "ECOG Performance Status 0-1",
    "Measurable disease per RECIST v1.1"
  ],
  "exclusion_criteria": [
    "Prior treatment with KRAS G12C inhibitor",
    "Symptomatic brain metastases",
    "Significant cardiovascular disease"
  ],
  "arms": [
    {
      "name": "Treatment Arm A",
      "intervention": "LA-KRAS-001 200mg BID",
      "patients": 60
    },
    {
      "name": "Treatment Arm B", 
      "intervention": "LA-KRAS-001 400mg QD",
      "patients": 60
    }
  ],
  "biomarkers": [
    "ctDNA KRAS G12C VAF",
    "PD-L1 expression",
    "TMB score"
  ],
  "data_cutoff_date": "2024-12-31",
  "safety_monitoring": "Independent Data Monitoring Committee"
}
